Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant - Takeaways - MDSpire

Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant

  • By

  • Benjamin A. Derman

  • Jennifer Cooperrider

  • Jacalyn Rosenblatt

  • David E. Avigan

  • Murtuza Rampurwala

  • David Barnidge

  • Ajay Major

  • Theodore Karrison

  • Ken Jiang

  • Aubrianna Ramsland

  • Tadeusz Kubicki

  • Andrzej J. Jakubowiak

  • May 29, 2024

  • 0 min

Share

  • 1

    The phase II trial evaluated the efficacy of an ASCT-free approach using daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma.

  • 2

    A total of 42 patients were enrolled, with a median age of 58 years, and 57% had high-risk cytogenetic abnormalities.

  • 3

    The primary endpoint was the rate of stringent complete response (sCR) and/or minimal residual disease (MRD) negativity at the end of 8 cycles.

  • 4

    The study found that 95% of patients were evaluated for response, with a median of 23 cycles received by participants.

  • 5

    Results indicated high rates of deep and durable responses, supporting the potential of Dara-KRd without ASCT in treating NDMM.

Original Source(s)

Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant

  • by Benjamin A. Derman, Jennifer Cooperrider, Jacalyn Rosenblatt, David E. Avigan, Murtuza Rampurwala, David Barnidge, Ajay Major, Theodore Karrison, Ken Jiang, Aubrianna Ramsland, Tadeusz Kubicki, Andrzej J. Jakubowiak

  • May 29, 2024

Related Content

CRISPR Enables In Vivo CAR T Cell Production

In vivo gene editing strategy generates CAR T cells directly inside the body – sidestepping costly manufacturing

  • March 30, 2026

  • 2 min
Financial toxicity as logistical and relational burden across the lifespan during autologous transplant preparation

Clinical Reasoning in Practice: Implementing High-Value Care When Data Discrepancies Arise